Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/16/26 18:08 | 6/12/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Ra Capital Management, L.P. | MA | DT | 3 | P.dm | 87,250 | 10.81 | 0 | 8,069 | 82 | 17,923 | I | |||||||||||||||
5/28/26 16:34 | 5/11/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Gc Corp. | T | 1 | P | 16,500 | 11.52 | 0 | 1,432 | 31 | 6,000 | M | ||||||||||||||||
5/19/26 21:52 | 5/19/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Raymon Heather | CA | O | SVP,Rese | 1 | S | -28 | 9.01 | 0 | -3 | 148 | D | |||||||||||||||
5/19/26 21:52 | 5/19/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Horan Christopher | CA | O | Chief Te | 1 | S | -63 | 9.01 | 0 | -7 | 293 | D | |||||||||||||||
5/19/26 21:51 | 5/19/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Bush Jennifer | CA | O | COO,CLO, | 1 | S | -79 | 9.01 | 0 | -9 | 338 | D | |||||||||||||||
5/19/26 21:50 | 5/19/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Banerjee Subhashis | CA | O | Chief Me | 1 | S | -63 | 9.01 | 0 | -7 | 145 | D | |||||||||||||||
5/19/26 21:50 | 5/19/26 | ARTV | Health | BioPrd | Biological Products, (No Diag | Aslan Fred | CA | DO | CEO | 1 | S | -244 | 9.01 | 0 | -27 | 1,535 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |